EUCTR2006-000570-78-IT进行中（未招募）不适用
PHASE I/II STUDY OF TEMOZOLOMIDE COMBINED WITH ORAL ETOPOSIDE IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA COHORT A , AND MALIGNANT GLIAL TUMOUR COHORT B - ND
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点目标入组 24 人开始时间: 2006年11月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age at inclusion 3 years and 21 years Life expectancy 8 weeks Lansky 16 years or Karnofsky 16 years score 30 see appendix The patients should be neurologically stable or improving during the week before starting chemotherapy Haematology o Neutrophils 8805; 1.0 x109/l and o Platelets 8805; 100 x109/l Liver function o Bilirubin 8804; 1.5 x normal upper limito AST and ALT 8804; 2.5 x normal upper limit
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnant or lactating females Other concomitant investigate treatment for PNET/medulloblastoma and malignant glial tumours Severe or life threatening infection Previous treatment with single TMZ or oral VP-16
研究者
相似试验
进行中（未招募）
不适用
PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECANIN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS - TOTEM 2EUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURSMedDRA version: 9.1Level: PTClassification code 10029260MedDRA version: 9.1Level: PTClassification code 10039491EUCTR2009-012644-16-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI93
已完成
不适用
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)-C189 Colon, unspecified-C349 Bronchus or lung, unspecified-C760 Head, face and neck-C159 Oesophagus, unspecifiedOesophagus, unspecifiedColon, unspecifiedBronchus or lung, unspecifiedHead, face and neckC159C189C349C760PER-023-07SCHERING PLOUGH RESEARCH INSTITUTE,
进行中（未招募）
1 期
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) PromoterAdvanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head and Neck (H&N), Esophageal CancerMedDRA version: 8.1 Level: LLT Classification code 10028980 Term: NeoplasmEUCTR2006-003169-15-CZSchering Plough Research Institute160
进行中（未招募）
1 期
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) PromoterAdvanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head and Neck (H&N), Esophageal CancerMedDRA version: 8.1 Level: LLT Classification code 10028980 Term: NeoplasmEUCTR2006-003169-15-GBSchering Plough Research Institute160
进行中（未招募）
不适用
A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) PromoterEUCTR2006-003169-15-SESchering Plough Research Institute160